All Stories

  1. Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

    Article • BMJ Open Diabetes Research & Care, January 2020, BMJ

    Barnaby Hunt

  2. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin

    Article • Journal of Medical Economics, November 2019, Taylor & Francis

    Barnaby Hunt

  3. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

    Article • BMJ Open Diabetes Research & Care, October 2019, BMJ

    Barnaby Hunt

  4. Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy

    Article • ClinicoEconomics and Outcomes Research, October 2019, Taylor & Francis

    Barnaby Hunt

  5. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

    Article • Journal of Medical Economics, August 2019, Taylor & Francis

    Professor Stephen Charles Bain, Mr Barrie D Chubb, Brian Bekker Hansen, Barnaby Hunt, Emma McBeath

  6. Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA

    Article • ClinicoEconomics and Outcomes Research, March 2019, Dove Medical Press

    Ms Michelle Mocarski, Barnaby Hunt

  7. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US

    Article • Journal of Medical Economics, September 2018, Taylor & Francis

    Ms Michelle Mocarski, Barnaby Hunt

  8. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system

    Article • ClinicoEconomics and Outcomes Research, December 2017, Dove Medical Press

    Barnaby Hunt

  9. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States

    Article • Journal of Medical Economics, July 2017, Taylor & Francis

    Cory Gamble, Barnaby Hunt

  10. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA

    Article • Journal of Medical Economics, March 2017, Taylor & Francis

    Ms Michelle Mocarski, Barnaby Hunt

  11. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes

    Article • ClinicoEconomics and Outcomes Research, October 2016, Dove Medical Press

    Barnaby Hunt

  12. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries

    Article • Medical Devices Evidence and Research, November 2012, Taylor & Francis

    Barnaby Hunt